CN-121971454-A - Application of composition containing tanshinone extract and musk ketone

Abstract

The invention discloses an application of a composition containing tanshinone extract and musk ketone, belonging to the technical field of medicines. The compatibility and the proportion control of the tanshinone extract and the musk ketone can inhibit the expression and/or secretion of FSTL1 of cardiac ciliated cells on the molecular level, regulate and control related fibrosis signal paths, thereby inhibiting the myocardial fibrosis process, generating synergistic effect with myocardial injury resistance, improving the ventricular structure and abnormal functions after myocardial infarction, and being used for treating cardiovascular diseases such as myocardial infarction, myocardial fibrosis, heart failure after myocardial infarction and the like. The composition of the invention comprises tanshinone extract and musk ketone, and can be used for preparing medicines with better effect for preventing and treating cardiovascular diseases.

Inventors

• YU JINGZHI
• DU GUANHUA
• LI XIAOYU
• LI FENG
• WANG XINMING
• DU LIDA
• JIAO ZIQI

Assignees

• 山东省中医药研究院
• 山东济世药业有限公司

Dates

Publication Date

20260505

Application Date

20260408

Claims (10)

1. 1. Use of a composition comprising tanshinone extract and muscone for preparing medicine for inhibiting secretion of FSTL1 by cardiac ciliated cells.
2. 2. The use according to claim 1, wherein the mass ratio of tanshinone extract to musk ketone is (1-30): 1.
3. 3. The use according to claim 1, wherein the active ingredient of the tanshinone extract comprises any one or more of tanshinone I, tanshinone IIA, tanshinone IIB, cryptotanshinone, dihydrotanshinone.
4. 4. The use according to claim 1, wherein the composition further comprises an adjuvant.
5. 5. The use according to claim 4, wherein the adjuvant comprises any one or more of diluents, suspending agents, stabilizers, wetting agents, preservatives and flavouring agents.
6. 6. The use according to claim 1, wherein the dosage form of the composition comprises a tablet, a pill, a capsule, a granule, an oral liquid or a suspension.
7. 7. The use according to claim 1, wherein the tanshinone extract is prepared by a process comprising: pulverizing Saviae Miltiorrhizae radix or Saviae Miltiorrhizae radix plant into coarse powder, adding into ethanol, heating and refluxing at 80-90deg.C for three times, filtering, mixing filtrates, and concentrating under reduced pressure to obtain soft extract with relative density of 1.30-1.35; Washing the soft extract with hot water until the water phase is colorless, drying at 80deg.C, and pulverizing to obtain tanshinone extract.
8. 8. Use according to claim 1, characterized in that the musk ketone is a monomeric compound obtained by extraction or synthesis, with a purity of 80% to 99.9%.
9. 9. A composition containing tanshinone extract and muscone is used for preparing medicine for treating cardiovascular diseases.
10. 10. The use according to claim 9, wherein the cardiovascular disease comprises any one or more of myocardial infarction, myocardial fibrosis, post myocardial ventricular remodeling and post myocardial heart failure.

Description

Application of composition containing tanshinone extract and musk ketone Technical Field The invention belongs to the technical field of medicines, and relates to application of a composition containing tanshinone extract and musk ketone. Background Myocardial infarction (myocardial infarction, MI) is a serious cardiovascular disease resulting from acute or persistent ischemia and hypoxia of the coronary arteries leading to myocardial cell necrosis, and is one of the leading causes of heart failure and cardiac death. After myocardial infarction, an inflammatory response and tissue repair process occurs in the damaged myocardial area, in which fibroblasts activate and secrete extracellular matrix in large amounts, ultimately leading to myocardial fibrosis and ventricular remodeling. Excessive myocardial fibrosis can lead to reduced myocardial compliance, abnormal changes in ventricular structure and function, and further progression to heart failure. Therefore, inhibition of myocardial fibrosis after myocardial infarction and improvement of ventricular remodeling have become one of the important directions of current therapeutic research for cardiovascular diseases. At present, the clinic treatment for myocardial infarction and complications thereof mainly comprises antiplatelet drugs, beta receptor blockers, angiotensin converting enzyme inhibitors (angiotensin converting enzyme inhibitors, ACEI), angiotensin receptor blockers (Angiotensin Receptor Blocker, ARB) and other drugs. These drugs can improve myocardial ischemia and delay ventricular remodeling to some extent, but direct intervention for myocardial fibrosis is still limited. The traditional Chinese medicine and the active ingredients thereof have a certain research basis in the aspect of preventing and treating cardiovascular diseases. For example, the preparation raw materials of the compound xiangdan granule reported in the prior literature comprise red sage root, ginseng, haw leaf and artificial musk, which are used for improving the treatment of myocardial ischemia or coronary heart disease, but the intervention effect of myocardial fibrosis and ventricular remodeling after myocardial infarction is not studied. Disclosure of Invention The invention aims to provide an application of a composition containing tanshinone extract and musk ketone, which solves the problem that the existing medicine cannot effectively interfere with myocardial fibrosis after myocardial infarction and ventricular remodeling after myocardial infarction. In order to achieve the above purpose, the present invention adopts the following technical scheme: In a first aspect, the present invention provides the use of a composition comprising a tanshinone extract and muscone for the preparation of a medicament for inhibiting cardiac fibroblast-derived FSTL1 (Follistatin-like protein 1). In a second aspect, the present invention provides the use of another composition comprising a tanshinone extract and musk ketone for the manufacture of a medicament for the treatment of cardiovascular diseases, wherein the cardiovascular diseases comprise any one or more of myocardial infarction, myocardial fibrosis, ventricular remodeling after myocardial infarction and heart failure after myocardial infarction. The invention has the following beneficial effects: (1) In the invention, the compatibility and the proportion control of the tanshinone extract and the musk ketone can inhibit the expression or secretion of FSTL1 by cardiac ciliated cells and regulate and control related fibrosis signal paths, thereby inhibiting the myocardial fibrosis process at the molecular level and generating synergistic effect in the aspects of resisting myocardial injury and inhibiting fibrosis, thereby improving the overall treatment effect of the composition. (2) The composition can obviously inhibit the activation of cardiac fibroblasts after myocardial infarction and reduce collagen deposition, thereby reducing the degree of myocardial fibrosis, improving the structural and functional abnormality of heart chambers after myocardial infarction, and is used for treating cardiovascular diseases such as myocardial infarction, myocardial fibrosis, heart failure after myocardial infarction and the like. (3) The composition only comprises two active ingredients of tanshinone extract and musk ketone, and is beneficial to research on the action mechanism of medicines, standardized production and quality control. Drawings FIG. 1 is a UPLC-MS/MS (ultrahigh performance liquid chromatography TANDEM MASS chromatography-mass spectrometer) detection chart of tanshinone extract in the example of the present invention; FIG. 2 is a UPLC (ultrahigh performance liquid chromatography, high resolution liquid chromatograph) detection chart of tanshinone extract in the embodiment of the invention; FIG. 3 is a graph comparing results of ultrasonic M-type images and ultrasonic imaging of heart of mice in each group, wherein, A is a